HAP Trading’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-226,700
Closed -$144K 2309
2021
Q1
$144K Buy
+226,700
New +$9.98M 0.01% 843
2017
Q2
Sell
-16,700
Closed -$51K 926
2017
Q1
$51K Sell
16,700
-442,300
-96% -$15.6M ﹤0.01% 678
2016
Q4
$27K Buy
+459,000
New +$12.1M ﹤0.01% 731
2016
Q3
Sell
-16,300
Closed -$25K 1091
2016
Q2
$25K Sell
16,300
-3,600
-18% -$120K ﹤0.01% 694
2016
Q1
$15K Buy
+19,900
New +$434K ﹤0.01% 647

Other funds holding ACAD

HAP Trading's ACAD Position: Q4 2021 in Review

HAP Trading sold out of Acadia Pharmaceuticals (ACAD) in Q4 2021, closing a stake of 15,097 shares — an estimated $251K sold.

HAP Trading first reported a position in ACAD in Q3 2013 and held it in 5 quarters. The position peaked at $1.38M in Q1 2016. 247 funds tracked by Wall St. Rank hold ACAD as of Q4 2021.

  • HAP Trading reported no remaining Acadia Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • HAP Trading sold 15,097 Acadia Pharmaceuticals shares in Q4 2021, an estimated $251K.
  • HAP Trading first reported a position in Acadia Pharmaceuticals in Q3 2013 and held it in 5 quarters.
  • HAP Trading's Acadia Pharmaceuticals position peaked at $1.38M in Q1 2016.
  • 247 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2021.

Based on HAP Trading's 13F filing for Q4 2021, filed 14 Feb 2022.